Silexion Therapeutics to Present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Rhea-AI Summary

Silexion Therapeutics (NASDAQ:SLXN) said company management will present at Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 3, 2025 from 2:30–2:55pm ET at Florida Atlantic University Conference Center, Boca Raton, FL (Presentation Room 5).

Speakers include Ilan Hadar, CEO and Mirit Horenshtein-Hadar, CFO. Management will be available for one-on-one meetings by arrangement. A replay will be posted to Silexion's investor relations Events & Presentations page after the conference.

News Market Reaction

+20.42% 2.5x vol

15 alerts

+20.42% News Effect

+12.5% Peak Tracked

-2.7% Trough Tracked

+$2M Valuation Impact

$9M Market Cap

2.5x Rel. Volume

On the day this news was published, SLXN gained 20.42%, reflecting a significant positive market reaction. Argus tracked a peak move of +12.5% during that session. Argus tracked a trough of -2.7% from its starting point during tracking. Our momentum scanner triggered 15 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $2M to the company's valuation, bringing the market cap to $9M at that time. Trading volume was elevated at 2.5x the daily average, suggesting notable buying interest.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference date: December 3, 2025 Presentation time: 2:30–2:55pm ET Phase 2a trial: Phase 2a +1 more

4 metrics

Conference date December 3, 2025 Noble Capital Markets' 21st Annual Emerging Growth Equity Conference

Presentation time 2:30–2:55pm ET Scheduled company presentation slot at NobleCon21

Phase 2a trial Phase 2a Prior clinical trial of first‑generation product in solid tumors with mutated KRAS

Conference edition 21st Noble Capital Markets Emerging Growth Equity Conference (NobleCon21)

Market Reality Check

Price: $1.59 Vol: Volume 47,220 is below th...

normal vol

$1.59 Last Close

Volume Volume 47,220 is below the 20-day average of 61,699 (relative volume 0.77x). normal

Technical Shares at $3.04 are trading below the 200-day MA of $9.82 and far under the 52-week high of $63.45.

Peers on Argus

SLXN was down 1.31% while close biotech peers showed mixed moves: GLTO +2.55%, Q...

1 Down

SLXN was down 1.31% while close biotech peers showed mixed moves: GLTO +2.55%, QLGN +7.72%, BDRX +9.57%, DRMA -4.18%, ENTO -5.68%. Momentum scanner only flagged REVB at -5.05%, suggesting SLXN’s action was more stock-specific than a broad sector move.

Historical Context

5 past events · Latest: Dec 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 02	Clinical design feedback	Positive	-7.6%	German authority validated key elements of planned Phase 2/3 SIL204 trial.
Nov 26	Conference appearance	Neutral	+20.4%	Announcement of NobleCon21 presentation and availability for investor meetings.
Nov 25	Preclinical toxicology	Positive	+7.6%	Two‑species toxicology studies for SIL204 showed no systemic organ toxicity.
Nov 12	Earnings and update	Positive	+3.6%	Q3 results, increased cash, CRO selection, and progress toward Phase 2/3 start.
Sep 30	Preclinical efficacy data	Positive	+0.3%	SIL204 showed up to 99.7% inhibition across multiple KRAS‑driven cancer lines.

Pattern Detected

Recent news has mostly been clinically or financially positive, with share reactions usually positive but occasionally sharply negative, indicating inconsistent alignment between good news and price.

Recent Company History

Over the last few months, SLXN has reported multiple milestones around its KRAS-targeting candidate SIL204 and corporate progress. An Sep 30 preclinical update showed strong pan‑KRAS activity. A Nov 12 earnings update highlighted new funding and regained Nasdaq compliance. On Nov 25 and Dec 02, the company advanced toward a Phase 2/3 pancreatic cancer trial via toxicology completion and German regulatory feedback. The current NobleCon21 conference appearance (Nov 26) fits a pattern of active investor and clinical communication.

Regulatory & Risk Context

Active S-3 Shelf · $4.9 million

Shelf Active

Active S-3 Shelf Registration 2025-10-31

$4.9 million registered capacity

An effective resale S‑3 filed on Oct 31, 2025 covers up to 1,292,348 shares and 372 warrants for selling holders. SLXN would only receive up to $4.9 million if 344,063 registered warrants are exercised for cash, so the registration primarily enables secondary selling rather than direct company fundraising.

Market Pulse Summary

The stock surged +20.4% in the session following this news. A strong positive reaction aligns with S...

Analysis

The stock surged +20.4% in the session following this news. A strong positive reaction aligns with SLXN’s history of sizable moves around communications and milestones, as seen after past updates with moves like +20.42% and +7.62%. This conference news mainly increases visibility rather than changing fundamentals, while the stock still trades far below its $63.45 52‑week high and under the $9.82 200‑day MA. Investors have also faced overhang from an effective resale S‑3 that could enable additional share supply.

Key Terms

phase 2a clinical trial, oncology-focused biotechnology company, solid tumor cancers, kras oncogene

4 terms

phase 2a clinical trial medical

"The Company conducted a Phase 2a clinical trial in its first-generation product..."

A phase 2a clinical trial is an early-stage human study that tests a medical treatment in a small group of patients to learn whether it appears to work, to refine the right dose, and to monitor short-term safety. Investors watch these trials like prototype test drives: positive results reduce uncertainty about a drug’s chances, help estimate remaining development time and cost, and often trigger valuation changes or partnership interest in a drug program.

oncology-focused biotechnology company medical

"a clinical-stage, oncology-focused biotechnology company, today announced..."

A company that researches and develops medicines or treatments specifically for cancer and related disorders. For investors, such firms are like specialized designers: their value hinges on scientific breakthroughs, clinical trial progress, regulatory approvals, and potential market demand for a successful therapy, making them higher-risk but potentially high-reward bets compared with diversified drugmakers.

solid tumor cancers medical

"treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS..."

Solid tumor cancers are abnormal growths that form a mass in organs or tissues — like a lump in the lung, liver, breast or colon — as opposed to cancers that circulate in the blood. Investors watch them because treatments, trial results and approvals for drugs or devices targeting these tumors can drive large changes in a company’s revenue and valuation, much like a new technology that unlocks a big market.

kras oncogene medical

"cancers which have the mutated KRAS oncogene, generally considered to be the most common..."

KRAS oncogene is a gene that, when mutated, can drive cells to grow uncontrollably and form tumors; think of it as a car’s accelerator stuck in the “on” position. Investors care because KRAS mutations create clear targets for drugs, diagnostics, and clinical trials, shaping the market value of therapies and diagnostics, regulatory outcomes, and the outlook for companies developing treatments that can block or detect these mutations.

AI-generated analysis. Not financial advice.

Grand Cayman, Cayman Islands, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (“Silexion” or the “Company”), a clinical-stage, oncology-focused biotechnology company, today announced that Company management will be attending and presenting at the Noble Capital Markets' 21^st Annual Emerging Growth Equity Conference (NobleCon21).

Presentation details:
Type: Company presentation
Date: December 3, 2025
Time: 2:30 – 2:55pm ET
Speakers: Ilan Hadar, Chief Executive Officer and Mirit Horenshtein-Hadar, Chief Financial Officer
Location: Florida Atlantic University Conference Center, Boca Raton, FL, Presentation Room 5.

Silexion’s management will be available for one-on-one meetings during the conference. Interested parties should contact their conference representative to arrange a meeting.

Following the conference, a replay of the presentation will be posted to SIlexion’s investor relations website’s events and presentations page available using the following link: https://silexion.com/presentations/

About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical stage, oncology-focused biotechnology company dedicated to the development of innovative treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its first-generation product which showed a positive trend in comparison to the control of chemotherapy alone. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer. For more information please visit: https://silexion.com

Company Contact:
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com

Investor Contacts:
Arx Investor Relations
North American Equities Desk
silexion@arxhq.com

Chuck Padala 
LifeSci Advisors 
Chuck@lifesciadvisors.com

FAQ

When will Silexion (SLXN) present at NobleCon21?

Silexion will present on December 3, 2025 from 2:30–2:55pm ET.

Who will speak for Silexion (SLXN) at NobleCon21?

Speakers are Ilan Hadar, CEO, and Mirit Horenshtein-Hadar, CFO.

Where is Silexion's (SLXN) NobleCon21 presentation located?

The presentation is at Florida Atlantic University Conference Center, Boca Raton, FL, Presentation Room 5.

Will Silexion (SLXN) make the presentation available after NobleCon21?

Yes. A replay will be posted to Silexion's investor relations Events & Presentations page after the conference.

How can investors arrange one-on-one meetings with Silexion (SLXN) at NobleCon21?

Interested parties should contact their conference representative to arrange one-on-one meetings with management.

Where can I find more information about Silexion Therapeutics (SLXN)?

Company information and the presentation replay will be available at https://silexion.com/presentations/ and the company website.